StreetInsider.com News Articles

Form 144 DEXCOM INC Filed by: FOLETTA MARK G

Mon, 15 Jun 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260615/26648807.html

Form 144 DEXCOM INC Filed by: FOLETTA MARK G

Mon, 15 Jun 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260615/26648807.html

Form 144 DEXCOM INC Filed by: Brown Michael Jon

Mon, 15 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26647201.html

Form 144 DEXCOM INC Filed by: Brown Michael Jon

Mon, 15 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26647201.html

DexCom (DXCM) PT Raised to $88 at KeyBanc

Mon, 15 Jun 2026 06:53:21 -0400

KeyBanc raised its price target on DexCom (NASDAQ: DXCM) to $88.00 (from $75.00) while maintaining a Overweight rating.

FDA clears first over-the-counter glucose monitor for children

Fri, 12 Jun 2026 16:14:29 -0400

The U.S. Food and Drug Administration cleared Dexcom Inc.'s Stelo Glucose Biosensor System for over-the-counter use in children aged two years and older who do not use insulin. The clearance expands the device's availability beyond the adult population, for which it received approval in March 2024.

The continuous glucose monitor is indicated for children with diabetes who receive oral medication and individuals seeking to understand how diet, exercise and lifestyle changes affect glucose levels. The system uses a wearable sensor paired with a smartphone application to measure, record and display glucose values every 15 minutes.

Each sensor operates for up to 15

FDA clears Dexcom's over-the-counter glucose monitor for children

Fri, 12 Jun 2026 15:43:48 -0400

The U.S. Food and Drug Administration cleared Dexcom Inc.'s (NASDAQ: DXCM) Stelo Glucose Biosensor System for over-the-counter use in children aged two years and older who do not use insulin. The agency previously approved the device for adults 18 and older in March 2024.

The continuous glucose monitor uses a wearable sensor paired with a smartphone application to measure, record and display glucose values every 15 minutes. Each sensor operates for up to 15 days before replacement, though pediatric users may experience shorter wear times due to physiological and behavioral factors.

The device targets children with diabetes who receive oral medication and

FDA clears Dexcom's over-the-counter glucose monitor for children

Fri, 12 Jun 2026 15:43:48 -0400

The device targets children with diabetes who receive oral medication and

Pharmsource says it was unaware Dexcom sensors were stolen

Thu, 11 Jun 2026 06:23:31 -0400

Investing.com -- Drug wholesaler Pharmsource LLC said Thursday it did not know the Dexcom glucose sensors it purchased from licensed distributors had been marked for destruction, following warnings from the device maker that some units were stolen during disposal and resold.

Dexcom warned users in May that two lots of its G7 continuous glucose monitoring sensors were stolen during a destruction process and later sold by third parties. The company traced some of those sales to Pharmsource.

Brunswick, Georgia-based Pharmsource said it immediately conducted a full audit of its inventory and put remedial measures in place.

"Pharmsource had zero involvement in Dexcom's destruction

DexCom (DXCM) PT Raised to $95 at TD Cowen as 'CONNECT and MACE Data Impress at ADA'

Wed, 10 Jun 2026 08:30:03 -0400

TD Cowen analyst Joshua Jennings raised the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $75.00) while maintaining a Buy rating.

The analyst commented: "CONNECT and MACE Data Impress at ADA; DXCM is seemingly at the forefront of the T2NIT coverage expansion initiative, and we believe CONNECT represents a compelling dataset for payers. We see DXCM as a share gainer in the US T2NIT market, but believe incremental access should benefit all players due to the size of the opportunity and efforts from DXCM/ABT to address the different needs of less-intensive patients.

DXCM shares have been moving higher since the company's

DexCom (DXCM) PT Raised to $95 at TD Cowen as 'CONNECT and MACE Data Impress at ADA'

Wed, 10 Jun 2026 08:30:03 -0400

TD Cowen analyst Joshua Jennings raised the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $75.00) while maintaining a Buy rating.

DXCM shares have been moving higher since the company's

DexCom (DXCM) PT Raised to $85 at Mizuho

Tue, 09 Jun 2026 06:42:27 -0400

(Updated - June 9, 2026 6:42 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on DexCom (NASDAQ: DXCM) to $85.00 (from $75.00) while maintaining a Outperform rating.

The analyst commented: "We attended the 2026 American Diabetes Association (ADA) in New Orleans where Dexcom's (DXCM-OP) randomized control trial (RCT) comparing blood sugar control in Type 2 (T2D) non-insulin patients using continuous glucose monitoring (CGM) versus routine care using blood glucose meter (BGM) monitoring. The study achieved its primary endpoint of HbA1c reduction (measure of monthly average blood sugar) with the CGM achieving an average -1.6% decline versus an average -0.7% in

DexCom (DXCM) PT Raised to $85 at Mizuho

Tue, 09 Jun 2026 06:42:27 -0400

(Updated - June 9, 2026 6:42 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on DexCom (NASDAQ: DXCM) to $85.00 (from $75.00) while maintaining a Outperform rating.

Dexcom study shows glucose monitor reduces A1C in type 2 diabetes patients

Sat, 06 Jun 2026 15:18:29 -0400

DexCom Inc. (NASDAQ: DXCM) announced results from the CONNECT randomized controlled trial showing its G7 continuous glucose monitor led to a statistically significant reduction in A1C levels among people with type 2 diabetes not using insulin. The results were presented at the American Diabetes Association's Scientific Sessions in New Orleans.

The study included 283 participants across 22 primary care practices in the United States, with 265 completing the 26-week trial. Participants were randomly assigned to use either the Dexcom G7 or traditional blood glucose monitoring.

Participants using the Dexcom G7 experienced an average 1.6% A1C reduction from a baseline mean of 8.8%,

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin